Protein Therapeutics Market size is set to grow by USD 172.8 billion from 2024-2028, Increased demand for mAbs boost the market, Technavio

NEW YORK, June 10, 2024 /PRNewswire/ -- The global protein therapeutics market size is estimated to grow by USD 172.8 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  9.47%  during the forecast period. Increased demand for mabs is driving market growth, with a trend towards continued focus on improvement of protein therapeutics. However, complexities in manufacturing, storage conditions, distribution policies, and high cost  poses a challenge. Key market players include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Biocon Ltd., Biogen Inc., Bristol Myers Squibb Co., Celltrion Healthcare Co. Ltd., Creative Biolabs, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Intas Pharmaceuticals Ltd., Ipsen Pharma, Johnson and Johnson Services Inc., LGM Pharma LLC, Midas Pharma GmbH, Novartis AG, Novo Nordisk AS, Pfizer Inc., PV Pharma Healthcare Pvt. Ltd., and Sanofi SA.

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

Market Driver

In the Protein Therapeutics Market, companies are enhancing their product offerings to stay competitive. They are focusing on patients' needs to improve features for enhanced comfort. For example, LINET and LINAK introduce beds with unique features like four-section profiles and ultra-low beds. Four-section profiles offer better sitting positions with less compression, while ultra-low beds provide safer entry/exit heights. Additionally, manufacturers like Invacare extend maintenance schedules to reduce end-users' maintenance costs and increase sales. This product improvement trend is expected to boost the growth of the Protein Therapeutics Market. 

The Protein Therapeutics market is experiencing significant growth due to the increasing demand for effective treatments. Lumos Therapeutics and other key players are developing new proteins and technologies to treat various diseases. These proteins are used in therapies for a range of conditions, including chronic diseases and genetic disorders. Protochetics and Protemeics are important techniques used in the production of these proteins.

The use of delivery systems, such as peptides and proteins, is also a trend in this market. Genetically engineered proteins are also gaining popularity due to their ability to target specific diseases. The market for these therapies is expected to continue growing as research and development efforts yield new treatments. 

Research report provides comprehensive data on impact of trend. For more details- Download a Sample Report

Market Challenges

• The protein therapeutics market involves the production of complex proteins from living organisms, which is a time-consuming and costly process. This includes steps like fermentation, clarification, separation, purification, and formulation. Insulin, a protein, is produced through similar processes, requiring large investments in biotechnology and sterile facilities.
• Proper storage conditions are crucial to maintain product efficacy and increase costs. High development costs, complex manufacturing processes, and sterile conditions contribute to the high prices of protein therapeutics, posing challenges for end-users and insurers. Key products include LUCENTIS, Avastin, HUMIRA, and hemophilia A therapies, with costs ranging from USD1,800 to USD2,400 per month or USD2,000 per dose.
• The Protein Therapeutics Market faces several challenges in its growth. One significant challenge is the high cost of production. The complex process of producing proteins makes it expensive. Another challenge is the short half-life of many protein therapeutics, requiring frequent dosing and increasing treatment costs.
• Additionally, the development of biosimilars and generic versions of protein therapeutics is intensifying competition in the market. Furthermore, regulatory requirements for approval and stringent quality control measures add to the costs and complexity of bringing new protein therapeutics to market. Lastly, the need for personalized medicine and the development of new delivery systems present opportunities but also add to the challenges in the Protein Therapeutics Market.

For more insights on driver and challenges - Request a sample report!

Segment Overview 

1. Product 
• 1.1 mAbs
• 1.2 Human insulin
• 1.3 Erythropoeitin
• 1.4 Clotting factors
• 1.5 Others
2. Application 
• 2.1 Metabolic disorders
• 2.2 Immunologic disorders
• 2.3 Hematological disorders
• 2.4 Cancer
• 2.5 Genetic disorders
3. Geography 
• 3.1 North America
• 3.2 Europe
• 3.3 Asia
• 3.4 Rest of World (ROW)

1.1 mAbs-  Protein therapeutics market is experiencing significant growth due to increasing demand for effective treatments in various therapeutic areas. Biotechnology companies are investing heavily in research and development to bring new protein-based therapies to market. These therapies offer advantages such as high specificity, improved efficacy, and reduced side effects compared to traditional small molecule drugs. Protein therapeutics are used in treatments for conditions like cancer, neurological disorders, and inherited diseases. The market is expected to continue expanding as new applications and indications are discovered.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) - Download a Sample Report

Research Analysis

The Protein Therapeutics Market encompasses a range of treatments and medicines used in the management of various chronic disorders, including cancer, diabetes, autoimmune disorders, and cardiovascular diseases. This market is driven by the development of versatile therapies, such as Therapeutic protein drugs, which utilize both genetically engineered proteins and natural proteins. These proteins play a crucial role in modulating the activity of specific molecules and sugars, thereby influencing the progression of diseases.

The market for Protein Therapy is significant in major healthcare institutions, where treatments like Chemotherapy and Monoclonal antibodies segment are commonly administered for immunological diseases and hematological disorders. The Protein Therapy Market holds immense potential in Developing Economies, where the demand for quality drugs and advanced treatments continues to grow. Recombinant Proteins are a key segment of this market, offering effective solutions for metabolic disorders segment.

Market Research Overview

The Protein Therapeutics Market encompasses a range of therapeutic products derived from proteins, including monoclonal antibodies, enzymes, and peptides. These therapeutics offer unique advantages, such as high specificity and efficacy, making them valuable treatments for various diseases.

The market is driven by factors like increasing prevalence of chronic diseases, technological advancements in protein production, and growing demand for targeted therapies. Additionally, regulatory approvals and collaborations between academic institutions and biotech companies are further fueling market growth. Proteins are used in various therapeutic areas, including oncology, neurology, and immunology, among others. The market is expected to witness significant growth in the coming years due to these factors.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Product
• MAbs
• Human Insulin
• Erythropoeitin
• Clotting Factors
• Others
• Application
• Metabolic Disorders
• Immunologic Disorders
• Hematological Disorders
• Cancer
• Genetic Disorders
• Geography
• North America
• Europe
• Asia
• Rest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio